D
Pluri Inc.
PLUR
$4.72
$0.11412.48%
D
Sell
12/20/2024Upgraded
Pluri Inc. (PLUR) was upgraded to D- from E+ on 12/20/2024 due to an increase in the growth index, total return index and volatility index. Total revenue increased 239.58% from $96 to $326, EBIT increased 13.85% from -$6.03M to -$5.2M, and operating cash flow increased 5.77% from -$4.31M to -$4.06M.
Pluri Inc. (PLUR) was upgraded to D- from E+ on 12/20/2024 due to an increase in the growth index, total return index and volatility index. Total revenue increased 239.58% from $96 to $326, EBIT increased 13.85% from -$6.03M to -$5.2M, and operating cash flow increased 5.77% from -$4.31M to -$4.06M.
E
Sell
9/23/2024Downgrade
Pluri Inc. (PLUR) was downgraded to E+ from D- on 9/23/2024 due to a decline in the volatility index, total return index and growth index.
Pluri Inc. (PLUR) was downgraded to E+ from D- on 9/23/2024 due to a decline in the volatility index, total return index and growth index.
D
Sell
6/14/2024Upgraded
Pluri Inc. (PLUR) was upgraded to D- from E+ on 6/14/2024 due to an increase in the total return index, volatility index and growth index.
Pluri Inc. (PLUR) was upgraded to D- from E+ on 6/14/2024 due to an increase in the total return index, volatility index and growth index.
E
Sell
8/9/2023Downgrade
Pluri Inc. (PLUR) was downgraded to E+ from D- on 8/9/2023 due to a decline in the growth index and volatility index.
Pluri Inc. (PLUR) was downgraded to E+ from D- on 8/9/2023 due to a decline in the growth index and volatility index.
D
Sell
7/25/2023Upgraded
Pluri Inc. (PLUR) was upgraded to D- from E+ on 7/25/2023 due to an increase in the total return index and volatility index.
Pluri Inc. (PLUR) was upgraded to D- from E+ on 7/25/2023 due to an increase in the total return index and volatility index.
E
Sell
7/3/2023Downgrade
Pluri Inc. (PLUR) was downgraded to E+ from D- on 7/3/2023 due to a decline in the volatility index.
Pluri Inc. (PLUR) was downgraded to E+ from D- on 7/3/2023 due to a decline in the volatility index.
D
Sell
6/16/2023Upgraded
Pluri Inc. (PLUR) was upgraded to D- from E+ on 6/16/2023 due to a noticeable increase in the growth index and volatility index. Total revenue increased 4,250% from $2 to $87, earnings per share increased from -$0.2445 to -$0.1909, and operating cash flow increased 3.33% from -$6.28M to -$6.07M.
Pluri Inc. (PLUR) was upgraded to D- from E+ on 6/16/2023 due to a noticeable increase in the growth index and volatility index. Total revenue increased 4,250% from $2 to $87, earnings per share increased from -$0.2445 to -$0.1909, and operating cash flow increased 3.33% from -$6.28M to -$6.07M.
E
Sell
5/19/2023Downgrade
Pluri Inc. (PLUR) was downgraded to E+ from D- on 5/19/2023 due to a decline in the volatility index and total return index.
Pluri Inc. (PLUR) was downgraded to E+ from D- on 5/19/2023 due to a decline in the volatility index and total return index.
D
Sell
5/4/2023Upgraded
Pluri Inc. (PLUR) was upgraded to D- from E+ on 5/4/2023 due to an increase in the volatility index.
Pluri Inc. (PLUR) was upgraded to D- from E+ on 5/4/2023 due to an increase in the volatility index.
E
Sell
4/14/2023Downgrade
Pluri Inc. (PLUR) was downgraded to E+ from D- on 4/14/2023 due to a decline in the volatility index.
Pluri Inc. (PLUR) was downgraded to E+ from D- on 4/14/2023 due to a decline in the volatility index.
D
Sell
3/29/2023Upgraded
Pluri Inc. (PLUR) was upgraded to D- from E+ on 3/29/2023 due to an increase in the volatility index.
Pluri Inc. (PLUR) was upgraded to D- from E+ on 3/29/2023 due to an increase in the volatility index.
E
Sell
3/14/2023Downgrade
Pluri Inc. (PLUR) was downgraded to E+ from D on 3/14/2023 due to a decline in the growth index and total return index. Total revenue declined 97.7% from $87 to $2, and earnings per share declined from -$0.188 to -$0.2445.
Pluri Inc. (PLUR) was downgraded to E+ from D on 3/14/2023 due to a decline in the growth index and total return index. Total revenue declined 97.7% from $87 to $2, and earnings per share declined from -$0.188 to -$0.2445.
D
Sell
2/9/2023Upgraded
Pluri Inc. (PLUR) was upgraded to D from E+ on 02/09/2023.
Pluri Inc. (PLUR) was upgraded to D from E+ on 02/09/2023.
E
Sell
2/8/2023Downgrade
Pluri Inc. (PLUR) was downgraded to E+ from D on 2/8/2023 due to a noticeable decline in the solvency index and volatility index. Debt to equity increased from 0.74 to 0.88.
Pluri Inc. (PLUR) was downgraded to E+ from D on 2/8/2023 due to a noticeable decline in the solvency index and volatility index. Debt to equity increased from 0.74 to 0.88.
D
Sell
9/19/2022Upgraded
Pluri Inc. (PLUR) was upgraded to D from D- on 9/19/2022 due to an increase in the volatility index and total return index.
Pluri Inc. (PLUR) was upgraded to D from D- on 9/19/2022 due to an increase in the volatility index and total return index.
D
Sell
9/1/2022Downgrade
Pluri Inc. (PLUR) was downgraded to D- from D on 9/1/2022 due to a decline in the volatility index.
Pluri Inc. (PLUR) was downgraded to D- from D on 9/1/2022 due to a decline in the volatility index.
D
Sell
8/12/2022Upgraded
Pluri Inc. (PLUR) was upgraded to D from D- on 8/12/2022 due to an increase in the volatility index.
Pluri Inc. (PLUR) was upgraded to D from D- on 8/12/2022 due to an increase in the volatility index.
D
Sell
7/28/2022Downgrade
Pluri Inc. (PLUR) was downgraded to D- from D on 7/28/2022 due to a decline in the volatility index.
Pluri Inc. (PLUR) was downgraded to D- from D on 7/28/2022 due to a decline in the volatility index.
D
Sell
6/28/2022Upgraded
Pluristem Therapeutics Inc. (PSTI) was upgraded to D from D- on 6/28/2022 due to an increase in the total return index and volatility index.
Pluristem Therapeutics Inc. (PSTI) was upgraded to D from D- on 6/28/2022 due to an increase in the total return index and volatility index.
D
Sell
6/13/2022Downgrade
Pluristem Therapeutics Inc. (PSTI) was downgraded to D- from D on 6/13/2022 due to a decline in the volatility index.
Pluristem Therapeutics Inc. (PSTI) was downgraded to D- from D on 6/13/2022 due to a decline in the volatility index.
D
Sell
5/25/2022Upgraded
Pluristem Therapeutics Inc. (PSTI) was upgraded to D from D- on 5/25/2022 due to an increase in the growth index, solvency index and volatility index. The quick ratio increased from 6.06 to 7.92, earnings per share increased from -$0.3404 to -$0.3058, and operating cash flow increased 4.47% from -$9.86M to -$9.42M.
Pluristem Therapeutics Inc. (PSTI) was upgraded to D from D- on 5/25/2022 due to an increase in the growth index, solvency index and volatility index. The quick ratio increased from 6.06 to 7.92, earnings per share increased from -$0.3404 to -$0.3058, and operating cash flow increased 4.47% from -$9.86M to -$9.42M.
D
Sell
5/5/2022Upgraded
Pluristem Therapeutics Inc. (PSTI) was upgraded to D- from E+ on 5/5/2022 due to an increase in the total return index.
Pluristem Therapeutics Inc. (PSTI) was upgraded to D- from E+ on 5/5/2022 due to an increase in the total return index.
E
Sell
4/20/2022Downgrade
Pluristem Therapeutics Inc. (PSTI) was downgraded to E+ from D- on 4/20/2022 due to a decline in the total return index, growth index and volatility index. Operating cash flow declined 12.22% from -$8.79M to -$9.86M.
Pluristem Therapeutics Inc. (PSTI) was downgraded to E+ from D- on 4/20/2022 due to a decline in the total return index, growth index and volatility index. Operating cash flow declined 12.22% from -$8.79M to -$9.86M.
D
Sell
12/6/2021Downgrade
Pluristem Therapeutics Inc. (PSTI) was downgraded to D- from D on 12/6/2021 due to a decline in the total return index and volatility index.
Pluristem Therapeutics Inc. (PSTI) was downgraded to D- from D on 12/6/2021 due to a decline in the total return index and volatility index.
D
Sell
11/10/2021Upgraded
Pluristem Therapeutics Inc. (PSTI) was upgraded to D from D- on 11/10/2021 due to an increase in the growth index and valuation index. Earnings per share increased from -$0.4604 to -$0.36, EBIT increased 21.57% from -$14.59M to -$11.44M, and operating cash flow increased 8.42% from -$9.6M to -$8.79M.
Pluristem Therapeutics Inc. (PSTI) was upgraded to D from D- on 11/10/2021 due to an increase in the growth index and valuation index. Earnings per share increased from -$0.4604 to -$0.36, EBIT increased 21.57% from -$14.59M to -$11.44M, and operating cash flow increased 8.42% from -$9.6M to -$8.79M.
D
Sell
9/14/2021Downgrade
Pluristem Therapeutics Inc. (PSTI) was downgraded to D- from D on 9/14/2021 due to a large decline in the total return index, growth index and solvency index. Debt to equity increased from 0.01 to 0.43, operating cash flow declined 30.95% from -$7.33M to -$9.6M, and EBIT declined 2.54% from -$14.23M to -$14.59M.
Pluristem Therapeutics Inc. (PSTI) was downgraded to D- from D on 9/14/2021 due to a large decline in the total return index, growth index and solvency index. Debt to equity increased from 0.01 to 0.43, operating cash flow declined 30.95% from -$7.33M to -$9.6M, and EBIT declined 2.54% from -$14.23M to -$14.59M.
D
Sell
1/5/2021Downgrade
Pluristem Therapeutics Inc. (PSTI) was downgraded to D from D+ on 1/5/2021 due to a decline in the valuation index, volatility index and total return index.
Pluristem Therapeutics Inc. (PSTI) was downgraded to D from D+ on 1/5/2021 due to a decline in the valuation index, volatility index and total return index.
D
Sell
12/21/2020Upgraded
Pluristem Therapeutics Inc. (PSTI) was upgraded to D+ from D on 12/21/2020 due to a large increase in the total return index, solvency index and valuation index.
Pluristem Therapeutics Inc. (PSTI) was upgraded to D+ from D on 12/21/2020 due to a large increase in the total return index, solvency index and valuation index.
D
Sell
5/1/2020Upgraded
Pluristem Therapeutics Inc. (PSTI) was upgraded to D from D- on 5/1/2020 due to a noticeable increase in the volatility index, growth index and total return index. Earnings per share increased from -$0.4634 to -$0.3999, operating cash flow increased 12.98% from -$7.24M to -$6.3M, and EBIT increased 11.49% from -$7.2M to -$6.37M.
Pluristem Therapeutics Inc. (PSTI) was upgraded to D from D- on 5/1/2020 due to a noticeable increase in the volatility index, growth index and total return index. Earnings per share increased from -$0.4634 to -$0.3999, operating cash flow increased 12.98% from -$7.24M to -$6.3M, and EBIT increased 11.49% from -$7.2M to -$6.37M.
D
Sell
1/6/2020Upgraded
Pluristem Therapeutics Inc. (PSTI) was upgraded to D- from E+ on 1/6/2020 due to an increase in the volatility index and total return index.
Pluristem Therapeutics Inc. (PSTI) was upgraded to D- from E+ on 1/6/2020 due to an increase in the volatility index and total return index.
E
Sell
12/12/2019Downgrade
Pluristem Therapeutics Inc. (PSTI) was downgraded to E+ from D- on 12/12/2019 due to a decline in the volatility index, total return index and valuation index.
Pluristem Therapeutics Inc. (PSTI) was downgraded to E+ from D- on 12/12/2019 due to a decline in the volatility index, total return index and valuation index.
D
Sell
9/13/2019Upgraded
Pluristem Therapeutics Inc. (PSTI) was upgraded to D- from E+ on 9/13/2019 due to a noticeable increase in the growth index, valuation index and solvency index. The quick ratio increased from 1.31 to 3.08, earnings per share increased from -$0.8597 to -$0.529, and EBIT increased 23% from -$10.3M to -$7.93M.
Pluristem Therapeutics Inc. (PSTI) was upgraded to D- from E+ on 9/13/2019 due to a noticeable increase in the growth index, valuation index and solvency index. The quick ratio increased from 1.31 to 3.08, earnings per share increased from -$0.8597 to -$0.529, and EBIT increased 23% from -$10.3M to -$7.93M.
E
Sell
5/7/2019Downgrade
Pluristem Therapeutics Inc. (PSTI) was downgraded to E+ from D- on 5/7/2019 due to a significant decline in the growth index, solvency index and valuation index. The quick ratio declined from 2.05 to 1.31, EBIT declined 23.63% from -$8.33M to -$10.3M, and earnings per share declined from -$0.075 to -$0.086.
Pluristem Therapeutics Inc. (PSTI) was downgraded to E+ from D- on 5/7/2019 due to a significant decline in the growth index, solvency index and valuation index. The quick ratio declined from 2.05 to 1.31, EBIT declined 23.63% from -$8.33M to -$10.3M, and earnings per share declined from -$0.075 to -$0.086.
D
Sell
3/11/2016Downgrade
Pluristem Therapeutics, Inc. (PSTI) was downgraded to D- from D on 3/11/2016 due to a significant decline in the total return index, volatility index and efficiency index. Total capital declined 5.73% from $52.35M to $49.35M.
Pluristem Therapeutics, Inc. (PSTI) was downgraded to D- from D on 3/11/2016 due to a significant decline in the total return index, volatility index and efficiency index. Total capital declined 5.73% from $52.35M to $49.35M.
D
Sell
6/2/2014Downgrade
Pluristem Therapeutics, Inc. (PSTI) was downgraded to D from D+ on 6/2/2014 due to a significant decline in the volatility index, total return index and growth index.
Pluristem Therapeutics, Inc. (PSTI) was downgraded to D from D+ on 6/2/2014 due to a significant decline in the volatility index, total return index and growth index.
NASDAQ
03/17/2025 3:51PM Eastern
Quotes delayed
